Cargando…
Metronomic chemotherapy for indolent T‐cell lymphoproliferative disorder of the gastrointestinal tract
The present study proposes metronomic chemotherapy (CPT), including prednisolone, cyclophosphamide, and thalidomide, as a treatment for patients with severe symptomatic indolent T‐cell lymphoproliferative disorder of the gastrointestinal tract. The encouraging efficacy and excellent safety profile o...
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475756/ https://www.ncbi.nlm.nih.gov/pubmed/37340510 http://dx.doi.org/10.1111/cas.15880 |
| _version_ | 1785100784217620480 |
|---|---|
| author | Liu, Hailing Cao, Lei Zhao, Xiaoli Miao, Yi Wu, Wei Shi, Xiao Zhang, Xiaoyan Yin, Hua Zhu, Huayuan Xu, Wei Li, Jianyong Fan, Lei |
| author_facet | Liu, Hailing Cao, Lei Zhao, Xiaoli Miao, Yi Wu, Wei Shi, Xiao Zhang, Xiaoyan Yin, Hua Zhu, Huayuan Xu, Wei Li, Jianyong Fan, Lei |
| author_sort | Liu, Hailing |
| collection | PubMed |
| description | The present study proposes metronomic chemotherapy (CPT), including prednisolone, cyclophosphamide, and thalidomide, as a treatment for patients with severe symptomatic indolent T‐cell lymphoproliferative disorder of the gastrointestinal tract. The encouraging efficacy and excellent safety profile of CPT suggest the clinical potential of this combination. |
| format | Online Article Text |
| id | pubmed-10475756 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104757562023-09-05 Metronomic chemotherapy for indolent T‐cell lymphoproliferative disorder of the gastrointestinal tract Liu, Hailing Cao, Lei Zhao, Xiaoli Miao, Yi Wu, Wei Shi, Xiao Zhang, Xiaoyan Yin, Hua Zhu, Huayuan Xu, Wei Li, Jianyong Fan, Lei Cancer Sci LETTER TO THE EDITOR The present study proposes metronomic chemotherapy (CPT), including prednisolone, cyclophosphamide, and thalidomide, as a treatment for patients with severe symptomatic indolent T‐cell lymphoproliferative disorder of the gastrointestinal tract. The encouraging efficacy and excellent safety profile of CPT suggest the clinical potential of this combination. John Wiley and Sons Inc. 2023-06-20 /pmc/articles/PMC10475756/ /pubmed/37340510 http://dx.doi.org/10.1111/cas.15880 Text en © 2023 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
| spellingShingle | LETTER TO THE EDITOR Liu, Hailing Cao, Lei Zhao, Xiaoli Miao, Yi Wu, Wei Shi, Xiao Zhang, Xiaoyan Yin, Hua Zhu, Huayuan Xu, Wei Li, Jianyong Fan, Lei Metronomic chemotherapy for indolent T‐cell lymphoproliferative disorder of the gastrointestinal tract |
| title | Metronomic chemotherapy for indolent T‐cell lymphoproliferative disorder of the gastrointestinal tract |
| title_full | Metronomic chemotherapy for indolent T‐cell lymphoproliferative disorder of the gastrointestinal tract |
| title_fullStr | Metronomic chemotherapy for indolent T‐cell lymphoproliferative disorder of the gastrointestinal tract |
| title_full_unstemmed | Metronomic chemotherapy for indolent T‐cell lymphoproliferative disorder of the gastrointestinal tract |
| title_short | Metronomic chemotherapy for indolent T‐cell lymphoproliferative disorder of the gastrointestinal tract |
| title_sort | metronomic chemotherapy for indolent t‐cell lymphoproliferative disorder of the gastrointestinal tract |
| topic | LETTER TO THE EDITOR |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475756/ https://www.ncbi.nlm.nih.gov/pubmed/37340510 http://dx.doi.org/10.1111/cas.15880 |
| work_keys_str_mv | AT liuhailing metronomicchemotherapyforindolenttcelllymphoproliferativedisorderofthegastrointestinaltract AT caolei metronomicchemotherapyforindolenttcelllymphoproliferativedisorderofthegastrointestinaltract AT zhaoxiaoli metronomicchemotherapyforindolenttcelllymphoproliferativedisorderofthegastrointestinaltract AT miaoyi metronomicchemotherapyforindolenttcelllymphoproliferativedisorderofthegastrointestinaltract AT wuwei metronomicchemotherapyforindolenttcelllymphoproliferativedisorderofthegastrointestinaltract AT shixiao metronomicchemotherapyforindolenttcelllymphoproliferativedisorderofthegastrointestinaltract AT zhangxiaoyan metronomicchemotherapyforindolenttcelllymphoproliferativedisorderofthegastrointestinaltract AT yinhua metronomicchemotherapyforindolenttcelllymphoproliferativedisorderofthegastrointestinaltract AT zhuhuayuan metronomicchemotherapyforindolenttcelllymphoproliferativedisorderofthegastrointestinaltract AT xuwei metronomicchemotherapyforindolenttcelllymphoproliferativedisorderofthegastrointestinaltract AT lijianyong metronomicchemotherapyforindolenttcelllymphoproliferativedisorderofthegastrointestinaltract AT fanlei metronomicchemotherapyforindolenttcelllymphoproliferativedisorderofthegastrointestinaltract |